Argireline vs Palmitoyl Tripeptide-1
A side-by-side research comparison of Argireline and Palmitoyl Tripeptide-1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Argireline | Palmitoyl Tripeptide-1 |
|---|---|---|
| Full name | Argireline (Acetyl Hexapeptide-3) | Palmitoyl Tripeptide-1 (Pal-GHK) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Competes with SNAP-25 for position in SNARE complex, partially inhibiting vesicle docking and neurotransmitter release, reducing muscle contraction intensity. | Functions as matrikine signal, mimicking collagen fragments that trigger fibroblasts to produce new collagen. Palmitoyl enables deeper skin penetration. |
| Molecular weight | 889 Da | 578.8 Da |
| Half-life | 8-12 hours (topical) | 8-12 hours (topical) |
| Bioavailability | Moderate (topical) | Good (topical with lipid modification) |
| Typical dose | 5-10% solution | 2-5% in formulation |
| Frequency | 2x daily | 1-2x daily |
| Route | Topical | Topical |
Argireline reported benefits
- Reduces expression wrinkles up to 30%
- Non-invasive Botox alternative
- Prevents new wrinkle formation
- No muscle paralysis
- Stackable with other peptides
Palmitoyl Tripeptide-1 reported benefits
- Collagen synthesis stimulation
- Matrix remodeling
- Wrinkle reduction
- Skin thickness increase
Related comparisons
Research and educational reference only. Not medical advice.